Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 4, 2015, Pages 604-611

  Al Homsi, Ahmad Samer ^a,b   Roy, Tara S ^a   Cole, Kelli ^a   Feng, Yuxin ^a   Duffner, Ulrich ^b,c  

^a Spectrum Health   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Helen DeVos Children Hospital   (United States)

Author keywords

Cyclophosphamide; GVHD; GVHD prevention

Indexed keywords

CYCLOPHOSPHAMIDE; FAS ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOIMMUNIZATION; ANTIGEN EXPRESSION; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL DEATH; CLINICAL STUDY; DONOR; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; T CELL DEPLETION; ALLOGRAFT; GRAFT VS HOST DISEASE; LYMPHOCYTE DEPLETION; UNRELATED DONORS;

ALLOGRAFTS; CYCLOPHOSPHAMIDE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; UNRELATED DONORS;

EID: 84924248653     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.08.014     Document Type: Review

References (45)

1. Welniak L.A., Blazar B.R., Murohy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007, 25:139-170.
2. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. NEngl J Med 1986, 314:729-735.
3. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
4. Berenbaum M.C. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 1963, 200:84-85.
5. Whirl-Carrillo M., McDonagh E.M., Hebert J.M., et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Therap 2012, 92:414-417.
6. Emadi A., Jones R.J., Brodsky R.A. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009, 6:638-647.
7. Brodsky R.A., Petri M., Smith B.D., et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998, 129:1031-1035.
8. Strauss G., Osen W., Debatin K.M. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002, 128:255-266.
9. Berenbaum M.C. The effect of cytotoxic agents on the production of antibody to T.A.B. vaccine in the mouse. Biochem Pharmacol 1962, 11:29-44.
10. Berenbaum M.C., Brown I.N. Dose-response relationships for agents inhibiting the immune response. Immunology 1964, 7:65-71.
11. Nirmul G., Severin M.S., Taub R.N. Cyclophosphamide-induced immunologic tolerance to skin homografts. Surg Forum 1971, 22:287-288.
12. Nirmul G., Severin M.S., Taub R.N. Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice. Transplant Proc 1973, 5:675-678.
13. Mayumi H., Umesue M., Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996, 195:129-139.
14. Eto M., Mayumi H., Tomita Y., et al. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. JImmunol 1990, 145:1303-1310.
15. Matsuura A., Katsuno M., Suzuki Y., et al. Cyclophosphamide-induced tolerance in fully allogeneic heart transplantation in mice. Cell Immunol 1994, 155:501-507.
16. Kappler J.W., Staerz U., White J., Marrack P.C. Self-tolerance eliminates T cell specific Mls-modified products of the major histocompatibility complex. Nature 1988, 332:35-40.
17. MacDonald H.R., Schneider R., Lees R.K., et al. T-cell Vβ use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature 1988, 332:40-45.
18. Qin S., Cobbold S., Benjamin R., Waldmann H. Induction of classical transplantation tolerance in the adult. JExp Med 1989, 169:779-794.
19. Eto M., Mayumi H., Tomita Y., et al. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. JImmunol 1991, 146:1402-1409.
20. Huyan X.H., Lin Y.P., Gao T., et al. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. Int Immunopharmacol 2011, 11:1293-1297.
21. Ross D., Jones M., Komanduri K., Levy R.B. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013, 19:1430-1438.
22. Cieri N., Peccatori J., Oliveiera G., et al. Tracking T cell dynamics in the first month after haploidentical HSCT with post-transplant cyclophosphamide reveals a predominant contribution of memory stem T cells to the early phase of immune reconstitution. Blood 2013, 122:4615.
23. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. JExp Med 1982, 155:1063-1074.
24. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344.
25. Kanakry C.G., Ganguly S., Zahurak M., et al. Aldehyde dehydrogenase expression drives human regulatory T Cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013, 5:1-12.
26. Luznik L., O'Donnell P.V., Fuchs E.J. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT. Semin Oncol 2012, 39:683-693.
27. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386.
28. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
29. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:482-489.
30. Munchel A., Kesserwan C., Symons H.J., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high dose post-transplantation cyclophosphamide. Pediatr Rep 2011, 3(Suppl 2):43-47.
31. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
32. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. JClin Oncol 2013, 31:1310-1316.
33. Aversa F., Martelli M.F., Velardi A. Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adoptive immunity. Semin Oncol 2012, 39:643-652.
34. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
35. Bhamidipati P.K., DiPersio J.F., Stokerl-Goldstein K., et al. Haploidentical peripheral blood stem cell transplantation using non-myeloablative conditioning with post-transplant cyclophosphamide regimen is safe and is associated with very encouraging post-transplant outcomes. Blood 2013, 122:4532.
36. Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1835-1844.
37. Castagna L., Crocchiolo R., Furst S., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014, 20:724-729.
38. Gayoso J., Balsalobre P., Castilla-Llorente C., et al. Haploidentical stem cell transplantation (HAPLO-HSCT) with reduced intensity conditioning (RIC) regimens and high dose cylophosphamide post-transplant (HD-CY) as GVHD prophylaxis in patients with relapsed or refractory Hodgkin's disease: multicentric Spanish experience. Blood 2013, 122:3406.
39. Bolaños-Meade J., Fuchs E.J., Luznik L., et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012, 120:4285-4291.
40. Luznik L., Bolaños-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
41. Kanakry C.G., O'Donnell P., Furlong T., et al. Post-transplantation cyclophosphamide following busulfan and fludarabine myeloablative conditioning prevents severe acute and chronic graft-versus-host disease and minimizes duration of immunosuppression: results of a multi-institutional trial in patients with high-risk hematologic malignancies. Blood 2013, 122:3310.
42. Alousi A.M., Saliba R.M., Chen J., et al. Amatched controlled analysis of post-transplant cyclophosphamide (CY) versus tacrolimus and mini-dose methotrexate in matched sibling and unrelated donor transplant recipients receiving reduced-intensity conditioning: post-transplant CY is associated with higher rates of acute GVHD. Blood 2012, 120:4200.
43. Heine A., Held S.A.E., Daecke S.N., et al. The JAK-inhibitor impairs dendritic cell function invitro and invivo. Blood 2013, 122:1192-1202.
44. Choi S.W., Braun T., Chang L., et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haematopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014, 15:87-95.
45. Dezern A.E., Luznik L., Fuchs E.J., et al. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant 2011, 46:1012-1013.